Across TCGA pan-cancer cohorts, SNORC Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SNORC data layer compared with 28 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SNORC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNORC expression acts as an unfavorable survival marker.
HNSC and COAD are the cancer types where SNORC Mutation most reproducibly stratifies survival.